{"protocolSection":{"identificationModule":{"nctId":"NCT01355497","orgStudyIdInfo":{"id":"G300505"},"secondaryIdInfos":[{"id":"POWER2","type":"OTHER","domain":"GTx"}],"organization":{"fullName":"GTx","class":"INDUSTRY"},"briefTitle":"Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum","officialTitle":"Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy"},"statusModule":{"statusVerifiedDate":"2020-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-07"},"primaryCompletionDateStruct":{"date":"2013-05","type":"ACTUAL"},"completionDateStruct":{"date":"2014-06","type":"ACTUAL"},"studyFirstSubmitDate":"2011-05-12","studyFirstSubmitQcDate":"2011-05-16","studyFirstPostDateStruct":{"date":"2011-05-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-02-04","resultsFirstSubmitQcDate":"2020-10-26","resultsFirstPostDateStruct":{"date":"2020-11-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-10-26","lastUpdatePostDateStruct":{"date":"2020-11-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GTx","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.","detailedDescription":"This is a randomized, double blind, placebo controlled, multicenter, multinational efficacy and safety study in subjects with non small cell lung cancer. Subjects will be evenly randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary efficacy analysis will be based on total Lean Body Mass (LBM) and physical function."},"conditionsModule":{"conditions":["Muscle Wasting","Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":330,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GTx-024 3mg once daily","type":"EXPERIMENTAL","description":"subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial","interventionNames":["Drug: GTx-024"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","description":"subjects will be randomized to receive matching placebo once daily for the duration of the trial","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"GTx-024","description":"subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.","armGroupLabels":["GTx-024 3mg once daily"],"otherNames":["enobosarm, ostarine"]},{"type":"DRUG","name":"placebo","description":"subject will receive matching placebo for the duration of the trial","armGroupLabels":["placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Physical Function","description":"Measure is the percentage of subjects at day 84 with stair climb power change \\>=10% from their baseline value.","timeFrame":"Day 84"},{"measure":"Lean Body Mass","description":"Measure is the percentage of subjects at day 84 with lean body mass change \\>=0% from their baseline value.","timeFrame":"Day 84"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* give voluntary, signed informed consent in accordance with institutional policies\n* be non-obese as defined as body mass index (BMI)\\< or = 32 and weight \\< 300 pounds (\\< 136 kg)\n* have been diagnosed with Stage III or IV NSCLC\n* be prior to first line chemotherapy\n* planned first line chemotherapy regimen is platinum plus gemcitabine only or platinum plus vinorelbine only or platinum plus pemetrexed only\n* if surgery is part of the cancer treatment, screening for this study should be conducted at least 4 weeks (28 days) after surgery\n* life expectancy of \\> 6 months\n* ECOG score \\< or = 1\n* serum creatinine \\< or = 2.0 mg/dL\n* MALES - age \\> or = 30 years\n* \\- FEMALES - age \\>or=30 years and clinically confirmed as postmenopausal.Subjects must have undergone the onset of spontaneous or surgical menopause prior to the start of this study. Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for \\>or=6 months but \\<12 months they must have a serum FSH concentration of \\>or=50 mIU/mL and an estradiol concentration of \\<or=25 pg/mL. Surgical menopause is defined as bilateral oophorectomy.\n* MALES - subjects must agree to use a double barrier method of contraception during the study and for 3 months after study completion. This may include the following: condom + spermicide or condom + oral hormonal contraception\n* MALES - have a serum PSA of \\< or = 4.0 ng/mL or a negative prostate biopsy (no prostate cancer) within 6 months of evaluation\n\nExclusion Criteria:\n\n* Have, in the judgment of the Investigator, a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol\n* Have ALT/SGOT or AST/SGPT above 1.5 times the upper limit of normal (ULN) without evidence of liver metastases and above 5 times the ULN in subjects with evidence of liver metastases\n* have alkaline phosphatase greater than 3 times ULN and/or total bilirubin levels above 2 mg/dL at baseline\n* have biologic agents or kinase inhibitors as part of their first line chemotherapy regimen including, but not limited to bevacizumab (Avastin), gefitinib (Nexavar) and erlotinib (Tarceva)\n* cardiovascular: uncontrolled hypertension, congestive heart failure or angina\n* Pulmonary: Stage 4 chronic obstructive pulmonary disease (COPD)\n* positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), unless subject was diagnosed \\> 10 years prior to enrollment and no evidence of active liver disease\n* currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds including herbals), or antiandrogens; previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor for this study to determine appropriate washout period)\n* currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana (medical cannabis) or any prescription medication intended to increase appetite or treat unintentional weight loss\n* have a baseline stair climb time \\>or=30 seconds (mean of two stair climbs)\n* have active cancer, other than NSCLC or non-melanoma carcinoma of the skin, within the previous two years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"GTx Investigative Site","city":"Birmingham","state":"Alabama","zip":"35211","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"GTx Investigative Site","city":"Scottsdale","state":"Arizona","zip":"85255","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"GTx Investigative Site","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"GTx Investigative Site","city":"Long Beach","state":"California","zip":"90813","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"GTx Investigative Site","city":"Miami","state":"Florida","zip":"33133","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"GTx Investigative Site","city":"Orange City","state":"Florida","zip":"32763","country":"United States","geoPoint":{"lat":28.94888,"lon":-81.29867}},{"facility":"GTx Investigative Site","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"GTx Investigative Site","city":"Decatur","state":"Illinois","zip":"62526","country":"United States","geoPoint":{"lat":39.84031,"lon":-88.9548}},{"facility":"GTx Investigative Site","city":"Peoria","state":"Illinois","zip":"61615","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"GTx Investigative Site","city":"Skokie","state":"Illinois","zip":"60076","country":"United States","geoPoint":{"lat":42.03336,"lon":-87.73339}},{"facility":"GTx Investigative Site","city":"Goshen","state":"Indiana","zip":"46526","country":"United States","geoPoint":{"lat":41.58227,"lon":-85.83444}},{"facility":"GTx Investigative Site","city":"Indianapolis","state":"Indiana","zip":"46260","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"GTx Investigative Site","city":"Ashland","state":"Kentucky","zip":"41101","country":"United States","geoPoint":{"lat":38.47841,"lon":-82.63794}},{"facility":"GTx Investigative Site","city":"Concord","state":"Massachusetts","zip":"01742","country":"United States","geoPoint":{"lat":42.46037,"lon":-71.34895}},{"facility":"GTx Investigative Site","city":"Saint Clair Shores","state":"Michigan","zip":"48081","country":"United States","geoPoint":{"lat":42.49698,"lon":-82.88881}},{"facility":"GTx Investigative Site","city":"Tupelo","state":"Mississippi","zip":"38801","country":"United States","geoPoint":{"lat":34.25807,"lon":-88.70464}},{"facility":"GTx Investigative Site","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"GTx Investigative Site","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"GTx Investigative Site","city":"Burlington","state":"North Carolina","zip":"27215","country":"United States","geoPoint":{"lat":36.09569,"lon":-79.4378}},{"facility":"GTx Investigator","city":"Flat Rock","state":"North Carolina","zip":"28731","country":"United States","geoPoint":{"lat":35.27123,"lon":-82.44151}},{"facility":"GTx Investigative Site","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"GTx Investigative Site","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"GTx Investigative Site","city":"Canfield","state":"Ohio","zip":"44406","country":"United States","geoPoint":{"lat":41.02506,"lon":-80.76091}},{"facility":"Gabrail Cancer Center","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"GTx Investigative Site","city":"Sandusky","state":"Ohio","zip":"44870","country":"United States","geoPoint":{"lat":41.44894,"lon":-82.70796}},{"facility":"GTx Investigative Site","city":"Portland","state":"Oregon","zip":"97213","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"GTx Investigative Site","city":"Lancaster","state":"Pennsylvania","zip":"17604","country":"United States","geoPoint":{"lat":40.03788,"lon":-76.30551}},{"facility":"GTx Investigative Site","city":"Spartanburg","state":"South Carolina","zip":"29303","country":"United States","geoPoint":{"lat":34.94957,"lon":-81.93205}},{"facility":"GTx Investigative Site","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"GTx Investigative Site","city":"Round Rock","state":"Texas","zip":"78665","country":"United States","geoPoint":{"lat":30.50826,"lon":-97.6789}}]},"referencesModule":{"references":[{"pmid":"27138015","type":"DERIVED","citation":"Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"GTx-024 3mg Once Daily","description":"subjects will be randomized to receive GTx-024 for the duration of the trial\n\nGTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial."},{"id":"FG001","title":"Placebo","description":"subjects will be randomized to matching placebo once daily for the duration of the trial\n\nplacebo: subject will receive placebo for the duration of the trial"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"165"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"99"},{"groupId":"FG001","numSubjects":"102"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"66"},{"groupId":"FG001","numSubjects":"63"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"18"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"other-not provided","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"noncompliance","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"progressive disease","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"10"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Subjects included in the Full Analysis Set","groups":[{"id":"BG000","title":"GTx-024","description":"subjects will be randomized to receive GTx-024 for the duration of the trail\n\nGTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial."},{"id":"BG001","title":"Placebo","description":"subjects will be randomized to receive placebo for the duration of the trial\n\nplacebo: subject will receive placebo for the duration of the trial"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"320"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.0","lowerLimit":"41","upperLimit":"79"},{"groupId":"BG001","value":"62.0","lowerLimit":"40","upperLimit":"81"},{"groupId":"BG002","value":"61.0","lowerLimit":"40","upperLimit":"81"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"93"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"227"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Physical Function","description":"Measure is the percentage of subjects at day 84 with stair climb power change \\>=10% from their baseline value.","populationDescription":"Subjects included in the Full Analysis Set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of subjects","timeFrame":"Day 84","groups":[{"id":"OG000","title":"GTx-024","description":"subjects will be randomized to receive GTx-024 for the duration of the trail\n\nGTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial."},{"id":"OG001","title":"Placebo","description":"subjects will be randomized to receive placebo for the duration of the trial\n\nplacebo: subject will receive placebo for the duration of the trial"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"161"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","lowerLimit":"13.6","upperLimit":"26.5"},{"groupId":"OG001","value":"24.8","lowerLimit":"18.4","upperLimit":"32.3"}]}]}]},{"type":"PRIMARY","title":"Lean Body Mass","description":"Measure is the percentage of subjects at day 84 with lean body mass change \\>=0% from their baseline value.","populationDescription":"Subjects included in the Full Analysis Set","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of subjects","timeFrame":"Day 84","groups":[{"id":"OG000","title":"GTx-024","description":"subjects will be randomized to receive GTx-024 for the duration of the trail\n\nGTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial."},{"id":"OG001","title":"Placebo","description":"subjects will be randomized to receive placebo for the duration of the trial\n\nplacebo: subject will receive placebo for the duration of the trial"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"161"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","lowerLimit":"38.6","upperLimit":"54.6"},{"groupId":"OG001","value":"37.9","lowerLimit":"30.4","upperLimit":"45.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"1 year, 6 months","description":"Initiation: 29 Nov 2011, Completion: 30 May 2013","eventGroups":[{"id":"EG000","title":"GTx-024 3mg Once Daily","description":"subjects will be randomized to receive GTx-024 for the duration of the trial\n\nGTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial.","seriousNumAffected":109,"seriousNumAtRisk":165,"otherNumAffected":149,"otherNumAtRisk":165},{"id":"EG001","title":"Placebo Once Daily","description":"subjects will be randomized to receive placebo for the duration of the trial\n\nplacebo: subject will receive placebo for the duration of the trial","seriousNumAffected":113,"seriousNumAtRisk":165,"otherNumAffected":157,"otherNumAtRisk":165}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":165},{"groupId":"EG001","numAffected":9,"numAtRisk":165}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":165},{"groupId":"EG001","numAffected":10,"numAtRisk":165}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":165},{"groupId":"EG001","numAffected":5,"numAtRisk":165}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Febrile Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Bone Marrow Failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Hyperprothrombinaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Thrombotic Thrombocytopenic Purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Disease Progression","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":165},{"groupId":"EG001","numAffected":26,"numAtRisk":165}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Sudden Death","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Condition Aggravated","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"General Physical Health Deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":165},{"groupId":"EG001","numAffected":5,"numAtRisk":165}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Septic Shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Escherichia Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Infectious Pleural Effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Pneumonia Pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Pulmonary Haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Pulmonary Oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Acute Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Chronic Obstructive Pulmonary Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Hypercapnia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Respiratory Distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Erosive Duodentitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":165}]},{"term":"Gastric Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Gastrointestinal Inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Intestinal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Mesentaric Artery Thrombosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Peptic Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Upper Gastrointestinal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":165}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Cerebrovascular Accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":165},{"groupId":"EG001","numAffected":6,"numAtRisk":165}]},{"term":"Cognitive Disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Hypotonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Loss Of Consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Neropathy Peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Optic Neuritis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Metastases To Central Nervous System","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Cancer Pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Metastatic Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Tumour Associated Fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Tumour Compression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":2,"numAtRisk":165}]},{"term":"Cardiac Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Acute Coronary Syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Cardiac Failure Acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Cardiac Failure Congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":3,"numAtRisk":165}]},{"term":"Renal Failure Acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Renal Impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Lymphoedema","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Peripheral Artery Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Superior Vena Cava Syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Blood Urea Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Hepatic Enzyme Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Platelet Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Pain In Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Rheumatoid Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Liver Disorder","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Fractured Sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Spinal Compression Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Completed Suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Confusional State","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":165}]},{"term":"Haemorrhagic Arteriovenous Malformation","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]},{"term":"Inappropriate Antidiuretic Hormone Secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":165},{"groupId":"EG001","numAffected":0,"numAtRisk":165}]},{"term":"Anaphylactic Reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":165},{"groupId":"EG001","numAffected":1,"numAtRisk":165}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":143,"numAffected":84,"numAtRisk":165},{"groupId":"EG001","numEvents":119,"numAffected":79,"numAtRisk":165}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":92,"numAffected":51,"numAtRisk":165},{"groupId":"EG001","numEvents":114,"numAffected":56,"numAtRisk":165}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":31,"numAtRisk":165},{"groupId":"EG001","numEvents":55,"numAffected":29,"numAtRisk":165}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":26,"numAtRisk":165},{"groupId":"EG001","numEvents":52,"numAffected":28,"numAtRisk":165}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":153,"numAffected":74,"numAtRisk":165},{"groupId":"EG001","numEvents":168,"numAffected":73,"numAtRisk":165}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":81,"numAffected":45,"numAtRisk":165},{"groupId":"EG001","numEvents":82,"numAffected":48,"numAtRisk":165}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":21,"numAtRisk":165},{"groupId":"EG001","numEvents":33,"numAffected":25,"numAtRisk":165}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":15,"numAtRisk":165},{"groupId":"EG001","numEvents":23,"numAffected":17,"numAtRisk":165}]},{"term":"Disease Progression","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":29,"numAtRisk":165},{"groupId":"EG001","numEvents":36,"numAffected":31,"numAtRisk":165}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":26,"numAtRisk":165},{"groupId":"EG001","numEvents":41,"numAffected":29,"numAtRisk":165}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":25,"numAtRisk":165},{"groupId":"EG001","numEvents":35,"numAffected":27,"numAtRisk":165}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":19,"numAtRisk":165},{"groupId":"EG001","numEvents":29,"numAffected":20,"numAtRisk":165}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":165},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":165}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":165},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":165}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":19,"numAtRisk":165},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":165}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":21,"numAtRisk":165},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":165}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":165},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":165}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":32,"numAtRisk":165},{"groupId":"EG001","numEvents":37,"numAffected":28,"numAtRisk":165}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":165},{"groupId":"EG001","numEvents":15,"numAffected":12,"numAtRisk":165}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":23,"numAtRisk":165},{"groupId":"EG001","numEvents":22,"numAffected":15,"numAtRisk":165}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":165},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":165}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":165},{"groupId":"EG001","numEvents":20,"numAffected":16,"numAtRisk":165}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":165},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":165}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":18,"numAtRisk":165},{"groupId":"EG001","numEvents":19,"numAffected":17,"numAtRisk":165}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (13.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":165},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":165}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Provide Sponsor with an advance copy of any proposed results communication at least 60 days prior to the date of the planned submission or presentation and Sponsor shall have 60 days from receipt to request any changes. Sponsor may request a delay of up to 60 additional days.\n\nThe PI shall not present data until the earlier of Sponsor's publication of the results of all investigators participating in the Study or 18 months after completion of the Study at all participating sites."},"pointOfContact":{"title":"Senior Director, Clinical Operations","organization":"GTx Inc.","email":"mdesordi@gtxinc.com","phone":"1-901-261-3795"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D009133","term":"Muscular Atrophy"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D020879","term":"Neuromuscular Manifestations"},{"id":"D009461","term":"Neurologic Manifestations"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D001284","term":"Atrophy"},{"id":"D020763","term":"Pathological Conditions, Anatomical"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C547106","term":"ostarine"}]}},"hasResults":true}